Skip to main content
PMC home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 2005 Apr;81(954):236–242. doi: 10.1136/pgmj.2004.023309

Angiogenesis: a curse or cure?

K Gupta 1, J Zhang 1
PMCID: PMC1743249  PMID: 15811887

Abstract

Angiogenesis, the growth of new blood vessels is essential during fetal development, female reproductive cycle, and tissue repair. In contrast, uncontrolled angiogenesis promotes the neoplastic disease and retinopathies, while inadequate angiogenesis can lead to coronary artery disease. A balance between pro-angiogenic and antiangiogenic growth factors and cytokines tightly controls angiogenesis. Considerable progress has been made in identifying these molecular components to develop angiogenesis based treatments. One of the most specific and critical regulators of angiogenesis is vascular endothelial growth factor (VEGF), which regulates endothelial proliferation, permeability, and survival. Several VEGF based treatments including anti-VEGF and anti-VEGF receptor antibodies/agents are in clinical trials along with several other antiangiogenic treatments. While bevacizumab (anti-VEGF antibody) has been approved for clinical use in colorectal cancer, the side effects of antiangiogenic treatment still remain a challenge. The pros and cons of angiogenesis based treatment are discussed.

Full Text

The Full Text of this article is available as a PDF (90.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aiello L. P., Cahill M. T., Cavallerano J. D. Growth factors and protein kinase C inhibitors as novel therapies for the medical management diabetic retinopathy. Eye (Lond) 2004 Feb;18(2):117–125. doi: 10.1038/sj.eye.6700585. [DOI] [PubMed] [Google Scholar]
  2. Avecilla Scott T., Hattori Koichi, Heissig Beate, Tejada Rafael, Liao Fang, Shido Koji, Jin David K., Dias Sergio, Zhang Fan, Hartman Travis E. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med. 2003 Dec 21;10(1):64–71. doi: 10.1038/nm973. [DOI] [PubMed] [Google Scholar]
  3. Bainbridge James W. B., Mistry Ajay R., Thrasher Adrian J., Ali Robin R. Gene therapy for ocular angiogenesis. Clin Sci (Lond) 2003 Jun;104(6):561–575. doi: 10.1042/CS20020314. [DOI] [PubMed] [Google Scholar]
  4. Becerra S. P., Sagasti A., Spinella P., Notario V. Pigment epithelium-derived factor behaves like a noninhibitory serpin. Neurotrophic activity does not require the serpin reactive loop. J Biol Chem. 1995 Oct 27;270(43):25992–25999. doi: 10.1074/jbc.270.43.25992. [DOI] [PubMed] [Google Scholar]
  5. Bocci Guido, Francia Giulio, Man Shan, Lawler Jack, Kerbel Robert S. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A. 2003 Oct 15;100(22):12917–12922. doi: 10.1073/pnas.2135406100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Carmeliet P., Jain R. K. Angiogenesis in cancer and other diseases. Nature. 2000 Sep 14;407(6801):249–257. doi: 10.1038/35025220. [DOI] [PubMed] [Google Scholar]
  7. Chang Sung-Hee, Liu Catherine H., Conway Rebecca, Han David K., Nithipatikom Kasem, Trifan Ovidiu C., Lane Timothy F., Hla Timothy. Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci U S A. 2003 Dec 19;101(2):591–596. doi: 10.1073/pnas.2535911100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Doll Jennifer A., Stellmach Veronica M., Bouck Noël P., Bergh Anders R. J., Lee Chung, Abramson Lisa P., Cornwell Mona L., Pins Michael R., Borensztajn Jayme, Crawford Susan E. Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas. Nat Med. 2003 May 12;9(6):774–780. doi: 10.1038/nm870. [DOI] [PubMed] [Google Scholar]
  9. Eberhard A., Kahlert S., Goede V., Hemmerlein B., Plate K. H., Augustin H. G. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res. 2000 Mar 1;60(5):1388–1393. [PubMed] [Google Scholar]
  10. Fabbro Doriano, Parkinson David, Matter Alex. Protein tyrosine kinase inhibitors: new treatment modalities? Curr Opin Pharmacol. 2002 Aug;2(4):374–381. doi: 10.1016/s1471-4892(02)00179-0. [DOI] [PubMed] [Google Scholar]
  11. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol. 2001 Jun;280(6):C1358–C1366. doi: 10.1152/ajpcell.2001.280.6.C1358. [DOI] [PubMed] [Google Scholar]
  12. Ferrara N. VEGF: an update on biological and therapeutic aspects. Curr Opin Biotechnol. 2000 Dec;11(6):617–624. doi: 10.1016/s0958-1669(00)00153-1. [DOI] [PubMed] [Google Scholar]
  13. Ferrara Napoleone. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002 Oct;2(10):795–803. doi: 10.1038/nrc909. [DOI] [PubMed] [Google Scholar]
  14. Fidler Isaiah J., Ellis Lee M. Neoplastic angiogenesis--not all blood vessels are created equal. N Engl J Med. 2004 Jul 15;351(3):215–216. doi: 10.1056/NEJMp048080. [DOI] [PubMed] [Google Scholar]
  15. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971 Nov 18;285(21):1182–1186. doi: 10.1056/NEJM197111182852108. [DOI] [PubMed] [Google Scholar]
  16. Folkman Judah. Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002 Dec;29(6 Suppl 16):15–18. doi: 10.1053/sonc.2002.37263. [DOI] [PubMed] [Google Scholar]
  17. Fong T. A., Shawver L. K., Sun L., Tang C., App H., Powell T. J., Kim Y. H., Schreck R., Wang X., Risau W. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 1999 Jan 1;59(1):99–106. [PubMed] [Google Scholar]
  18. Galiano Robert D., Tepper Oren M., Pelo Catherine R., Bhatt Kirit A., Callaghan Matthew, Bastidas Nicholas, Bunting Stuart, Steinmetz Hope G., Gurtner Geoffrey C. Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. Am J Pathol. 2004 Jun;164(6):1935–1947. doi: 10.1016/S0002-9440(10)63754-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Gerber Hans-Peter, Malik Ajay K., Solar Gregg P., Sherman Daniel, Liang Xiao Huan, Meng Gloria, Hong Kyu, Marsters James C., Ferrara Napoleone. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature. 2002 Jun 27;417(6892):954–958. doi: 10.1038/nature00821. [DOI] [PubMed] [Google Scholar]
  20. Gorski D. H., Beckett M. A., Jaskowiak N. T., Calvin D. P., Mauceri H. J., Salloum R. M., Seetharam S., Koons A., Hari D. M., Kufe D. W. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 1999 Jul 15;59(14):3374–3378. [PubMed] [Google Scholar]
  21. Gupta K., Gupta P., Wild R., Ramakrishnan S., Hebbel R. P. Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: effect on human microvascular endothelial cell proliferation and angiogenesis. Angiogenesis. 1999;3(2):147–158. doi: 10.1023/a:1009018702832. [DOI] [PubMed] [Google Scholar]
  22. Gupta Kalpna, Kshirsagar Smita, Chang Liming, Schwartz Robert, Law Ping-Y, Yee Doug, Hebbel Robert P. Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res. 2002 Aug 1;62(15):4491–4498. [PubMed] [Google Scholar]
  23. Gutheil J. C., Campbell T. N., Pierce P. R., Watkins J. D., Huse W. D., Bodkin D. J., Cheresh D. A. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res. 2000 Aug;6(8):3056–3061. [PubMed] [Google Scholar]
  24. Holash J., Maisonpierre P. C., Compton D., Boland P., Alexander C. R., Zagzag D., Yancopoulos G. D., Wiegand S. J. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science. 1999 Jun 18;284(5422):1994–1998. doi: 10.1126/science.284.5422.1994. [DOI] [PubMed] [Google Scholar]
  25. Ishikawa M., Tanno K., Kamo A., Takayanagi Y., Sasaki K. Enhancement of tumor growth by morphine and its possible mechanism in mice. Biol Pharm Bull. 1993 Aug;16(8):762–766. doi: 10.1248/bpb.16.762. [DOI] [PubMed] [Google Scholar]
  26. Isner Jeffrey M. Myocardial gene therapy. Nature. 2002 Jan 10;415(6868):234–239. doi: 10.1038/415234a. [DOI] [PubMed] [Google Scholar]
  27. Kamphaus G. D., Colorado P. C., Panka D. J., Hopfer H., Ramchandran R., Torre A., Maeshima Y., Mier J. W., Sukhatme V. P., Kalluri R. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem. 2000 Jan 14;275(2):1209–1215. doi: 10.1074/jbc.275.2.1209. [DOI] [PubMed] [Google Scholar]
  28. Kerbel Robert, Folkman Judah. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2002 Oct;2(10):727–739. doi: 10.1038/nrc905. [DOI] [PubMed] [Google Scholar]
  29. Kirchner Loren M., Meerbaum Sharon O., Gruber Brian S., Knoll Andrew K., Bulgrin Jeffery, Taylor R. A. J., Schmidt Steven P. Effects of vascular endothelial growth factor on wound closure rates in the genetically diabetic mouse model. Wound Repair Regen. 2003 Mar-Apr;11(2):127–131. doi: 10.1046/j.1524-475x.2003.11208.x. [DOI] [PubMed] [Google Scholar]
  30. Koike Naoto, Fukumura Dai, Gralla Oliver, Au Patrick, Schechner Jeffrey S., Jain Rakesh K. Tissue engineering: creation of long-lasting blood vessels. Nature. 2004 Mar 11;428(6979):138–139. doi: 10.1038/428138a. [DOI] [PubMed] [Google Scholar]
  31. Le Gat L., Gogat K., Bouquet C., Saint-Geniez M., Darland D., Van Den Berghe L., Marchant D., Provost A., Perricaudet M., Menasche M. In vivo adenovirus-mediated delivery of a uPA/uPAR antagonist reduces retinal neovascularization in a mouse model of retinopathy. Gene Ther. 2003 Dec;10(25):2098–2103. doi: 10.1038/sj.gt.3302122. [DOI] [PubMed] [Google Scholar]
  32. Luttun Aernout, Tjwa Marc, Moons Lieve, Wu Yan, Angelillo-Scherrer Anne, Liao Fang, Nagy Janice A., Hooper Andrea, Priller Josef, De Klerck Bert. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med. 2002 Jul 1;8(8):831–840. doi: 10.1038/nm731. [DOI] [PubMed] [Google Scholar]
  33. Maeshima Y., Manfredi M., Reimer C., Holthaus K. A., Hopfer H., Chandamuri B. R., Kharbanda S., Kalluri R. Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin. J Biol Chem. 2001 Feb 7;276(18):15240–15248. doi: 10.1074/jbc.M007764200. [DOI] [PubMed] [Google Scholar]
  34. Maeshima Yohei, Sudhakar Akulapalli, Lively Julie C., Ueki Kohjiro, Kharbanda Surender, Kahn C. Ronald, Sonenberg Nahum, Hynes Richard O., Kalluri Raghu. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science. 2002 Jan 4;295(5552):140–143. doi: 10.1126/science.1065298. [DOI] [PubMed] [Google Scholar]
  35. Matsumoto K., Yoshitomi H., Rossant J., Zaret K. S. Liver organogenesis promoted by endothelial cells prior to vascular function. Science. 2001 Sep 27;294(5542):559–563. doi: 10.1126/science.1063889. [DOI] [PubMed] [Google Scholar]
  36. Nwogu J. I., Geenen D., Bean M., Brenner M. C., Huang X., Buttrick P. M. Inhibition of collagen synthesis with prolyl 4-hydroxylase inhibitor improves left ventricular function and alters the pattern of left ventricular dilatation after myocardial infarction. Circulation. 2001 Oct 30;104(18):2216–2221. doi: 10.1161/hc4301.097193. [DOI] [PubMed] [Google Scholar]
  37. Poonawala Tasneem, Levay-Young Brett K., Hebbel Robert P., Gupta Kalpna. Opioids heal ischemic wounds in the rat. Wound Repair Regen. 2005 Mar-Apr;13(2):165–174. doi: 10.1111/j.1067-1927.2005.130207.x. [DOI] [PubMed] [Google Scholar]
  38. Pugh Christopher W., Ratcliffe Peter J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med. 2003 Jun;9(6):677–684. doi: 10.1038/nm0603-677. [DOI] [PubMed] [Google Scholar]
  39. Rafii Shahin, Lyden David, Benezra Robert, Hattori Koichi, Heissig Beate. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer. 2002 Nov;2(11):826–835. doi: 10.1038/nrc925. [DOI] [PubMed] [Google Scholar]
  40. Rafii Shahin, Lyden David. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med. 2003 Jun;9(6):702–712. doi: 10.1038/nm0603-702. [DOI] [PubMed] [Google Scholar]
  41. Risau W. Mechanisms of angiogenesis. Nature. 1997 Apr 17;386(6626):671–674. doi: 10.1038/386671a0. [DOI] [PubMed] [Google Scholar]
  42. Ruzinova Marianna B., Schoer Rebecca A., Gerald William, Egan James E., Pandolfi Pier Paolo, Rafii Shahin, Manova Katia, Mittal Vivek, Benezra Robert. Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell. 2003 Oct;4(4):277–289. doi: 10.1016/s1535-6108(03)00240-x. [DOI] [PubMed] [Google Scholar]
  43. Savage David G., Antman Karen H. Imatinib mesylate--a new oral targeted therapy. N Engl J Med. 2002 Feb 28;346(9):683–693. doi: 10.1056/NEJMra013339. [DOI] [PubMed] [Google Scholar]
  44. Scappaticci Frank A. Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol. 2002 Sep 15;20(18):3906–3927. doi: 10.1200/JCO.2002.01.033. [DOI] [PubMed] [Google Scholar]
  45. Senger D. R., Galli S. J., Dvorak A. M., Perruzzi C. A., Harvey V. S., Dvorak H. F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983 Feb 25;219(4587):983–985. doi: 10.1126/science.6823562. [DOI] [PubMed] [Google Scholar]
  46. Takeuchi Yoshito, Kurohane Kohta, Ichikawa Kanae, Yonezawa Sei, Nango Mamoru, Oku Naoto. Induction of intensive tumor suppression by antiangiogenic photodynamic therapy using polycation-modified liposomal photosensitizer. Cancer. 2003 Apr 15;97(8):2027–2034. doi: 10.1002/cncr.11283. [DOI] [PubMed] [Google Scholar]
  47. Tarkka Tatu, Sipola Annina, Jämsä Timo, Soini Ylermi, Ylä-Herttuala Seppo, Tuukkanen Juha, Hautala Timo. Adenoviral VEGF-A gene transfer induces angiogenesis and promotes bone formation in healing osseous tissues. J Gene Med. 2003 Jul;5(7):560–566. doi: 10.1002/jgm.392. [DOI] [PubMed] [Google Scholar]
  48. Tepper Oren M., Sealove Brett A., Murayama Toshinori, Asahara Takayuki. Newly emerging concepts in blood vessel growth: recent discovery of endothelial progenitor cells and their function in tissue regeneration. J Investig Med. 2003 Nov;51(6):353–359. doi: 10.1136/jim-51-06-31. [DOI] [PubMed] [Google Scholar]
  49. Thorpe Philip E., Chaplin David J., Blakey David C. The first international conference on vascular targeting: meeting overview. Cancer Res. 2003 Mar 1;63(5):1144–1147. [PubMed] [Google Scholar]
  50. Tonini Tiziana, Rossi Francesca, Claudio Pier Paolo. Molecular basis of angiogenesis and cancer. Oncogene. 2003 Sep 29;22(42):6549–6556. doi: 10.1038/sj.onc.1206816. [DOI] [PubMed] [Google Scholar]
  51. Wang Lin, Schmitz Volker, Perez-Mediavilla Alberto, Izal Iñigo, Prieto Jesus, Qian Cheng. Suppression of angiogenesis and tumor growth by adenoviral-mediated gene transfer of pigment epithelium-derived factor. Mol Ther. 2003 Jul;8(1):72–79. doi: 10.1016/s1525-0016(03)00128-x. [DOI] [PubMed] [Google Scholar]
  52. Wedge Stephen R., Ogilvie Donald J., Dukes Michael, Kendrew Jane, Chester Rosemary, Jackson Janet A., Boffey Sarah J., Valentine Paula J., Curwen Jon O., Musgrove Helen L. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002 Aug 15;62(16):4645–4655. [PubMed] [Google Scholar]
  53. Wood J. M., Bold G., Buchdunger E., Cozens R., Ferrari S., Frei J., Hofmann F., Mestan J., Mett H., O'Reilly T. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000 Apr 15;60(8):2178–2189. [PubMed] [Google Scholar]
  54. Zhang Fan, Cheng Joseph, Hackett Neil R., Lam George, Shido Koji, Pergolizzi Robert, Jin David K., Crystal Ronald G., Rafii Shahin. Adenovirus E4 gene promotes selective endothelial cell survival and angiogenesis via activation of the vascular endothelial-cadherin/Akt signaling pathway. J Biol Chem. 2003 Dec 2;279(12):11760–11766. doi: 10.1074/jbc.M312221200. [DOI] [PubMed] [Google Scholar]
  55. Zhang J., Shen K-W, Liu G., Zhou J., Shen Q., Shen Z-Z, Shao Z-M. Antigenic profiles of disseminated breast tumour cells and microenvironment in bone marrow. Eur J Surg Oncol. 2003 Mar;29(2):121–126. doi: 10.1053/ejso.2002.1334. [DOI] [PubMed] [Google Scholar]
  56. Zondor Stacey D., Medina Patrick J. Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother. 2004 Jun 8;38(7-8):1258–1264. doi: 10.1345/aph.1D470. [DOI] [PubMed] [Google Scholar]
  57. Zwaginga J. J., Doevendans P. Stem cell-derived angiogenic/vasculogenic cells: possible therapies for tissue repair and tissue engineering. Clin Exp Pharmacol Physiol. 2003 Nov;30(11):900–908. doi: 10.1046/j.1440-1681.2003.03931.x. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES